CD274 and head and neck squamous cell carcinoma: Numerous phase I-III trials investigating PD-1/PD-L1 and/or CTLA-4 inhibitors are being initiated or are already running mainly investigating second line treatment after progression on platinum-based chemotherapy in patients with recurrent or metastatic HNSCC.